Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Update

18 Jan 2022 07:00

RNS Number : 7365Y
Elementis PLC
18 January 2022
 

Elementis plc

Trading Update

FY 21 adjusted operating profit modestly ahead of expectations

Leverage reduction on track

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues a trading update for the three months and year ended 31 December 2021.

Business performance

 

The Group has delivered a good fourth quarter performance, with double-digit year-on-year underlying revenue growth, agile supply chain management and self-help actions. As a result, adjusted operating profit for 2021 is expected to be in the range of $105-107m, modestly ahead of expectations*.

 

· Coatings performed well in Q4, and ahead of the prior year. As a result of pricing actions and volume growth, the business will deliver improved operating margins versus 2020.

 

· Personal Care performance in Q4 improved on the prior year. Demand continued to recover in cosmetics, as social and travel restrictions begin to ease, albeit still at levels below 2019.

 

· Talc performance in Q4 was below prior year as semi-conductor supply shortages continued to reduce automotive related demand.

· Chromium performance improved on the prior year as strong industrial demand was supported by improved pricing trends as global industry capacity utilisation increased.

 

In the fourth quarter we have continued to successfully deliver our Innovation, Growth and Efficiency strategy. For the full year 2021 we launched over 20 new products, won more than $35m of new business and delivered $10m of in year cost savings.

Balance Sheet

 

Net debt (excluding lease liabilities) at the end of 2021 is anticipated to be approximately $400m, representing a leverage ratio of 2.6x net debt to EBITDA**, and a significant reduction compared to 3.2x reported at the 31 December 2020.

 

Full 2021 results will be released on 3 March 2022 at 7am (UK) and will be available via the Elementis Plc website.

 

 

Enquiries

Elementis plc

James Curran, Investor Relations Tel: 020 7067 2994

 

Tulchan

Martin Robinson Tel: 020 7353 4200

Olivia Peters

 

* Based on company compiled consensus, the Board believes the average market forecast for 2021 adjusted operating profit to be $104m.

 

**Excluding IFRS 16 impact

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUPUGUPPGBM
Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.